Fiche société
Apellis Pharmaceuticals, Inc.
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications8liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Pegcetacoplan (APL-2)Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2 | À vérifier | United States, Australia, Belgium, Czechia, France, Germany, Ireland, Italy, … | À vérifier |
| Pegcetacoplan (APL-2)Description non affichée : incohérence de maladie détectée. Consultez l’essai clinique officiel associé. | Sclérose latérale amyotrophique | Phase 2 | À vérifier | United States, Australia, Belgium, Czechia, France, Germany, Ireland, Italy, Japan, Netherlands, Poland, Spain, Ukraine, United Kingdom | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Pegcetacoplan (APL-2) | Sclérose latérale amyotrophique | Phase 2 | NCT04579666 | MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS) | TERMINATED |
Publications
8| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Pegcetacoplan (APL-2) | Geographic atrophy: From slowing lesions to preserving vision. | Current opinion in ophthalmology | ||
| Pegcetacoplan (APL-2) | Switching patients with PNH from pegcetacoplan to iptacopan: a case series. | Hematology (Amsterdam, Netherlands) | ||
| Pegcetacoplan (APL-2) | Real-world pegcetacoplan treatment of paroxysmal nocturnal hemoglobinuria patients with an unsatisfactory response to prior therapies. | Hematology (Amsterdam, Netherlands) | ||
| Pegcetacoplan (APL-2) | Intraocular inflammation and presumed retinal vasculitis following initial pegcetacoplan intravitreal injection. | Digital journal of ophthalmology : DJO | ||
| Pegcetacoplan (APL-2) | Pegcetacoplan as a targeted C3 inhibitor in C3 glomerulopathy and immune-complex MPGN. | Annals of medicine and surgery (2012) | ||
| Pegcetacoplan (APL-2) | One-Year Results of Geographic Atrophy Patients with Pre-Existing nAMD treated with both anti-VEGF therapy and pegcetacoplan. | Retina (Philadelphia, Pa.) | ||
| Pegcetacoplan (APL-2) | Comparative Endophthalmitis Rates of Anti-VEGF, Corticosteroid Implants and Anti-Complement Injections: An IRIS® Registry Analysis. | American journal of ophthalmology | ||
| Pegcetacoplan (APL-2) | Virus-biomimetic melanin nanoparticles with spiky structures and neutral zwitterionic shell for non-invasive prevention of dry AMD. | Journal of controlled release : official journal of the Controlled Release Society |